文献速递脊柱关节炎

Ixekizumab对一种或两种TNF抑制剂应答不佳的银屑病关节炎患者的疗效

Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

SPIRIT-P2(NCT02349295)是一项3期研究的事后分析,评估Ixekizumab(IXE)对一种或两种TNF抑制剂(TNFi)应答不佳或不耐受的银屑病关节炎(PsA)患者的疗效。第24周时,无论既往TNFi经验如何,接受IXE的患者在ACR50、HAQ-DI≥0.35改善、MDA、EULAR良好反应和DAPSA≤14方面均显著优于安慰剂;对一种TNFi应答不佳者中,IXE组ACR50和PASI 100也显著优于安慰剂。所有指标改善持续至第52周。

要点

  • 对一种或两种TNFi应答不佳的PsA患者,IXE在多项疗效指标上优于安慰剂。
  • 对一种TNFi应答不佳者,IXE组ACR50和PASI 100达到率显著高于安慰剂。
  • IXE的疗效改善在所有指标中持续至第52周。

核心结论

  • IXE可改善对一种或两种TNFi应答不佳的难治性PsA患者的体征和症状。

研究设计与样本

  • SPIRIT-P2(NCT02349295)3期研究的事后分析,纳入对一种或两种TNFi应答不佳或不耐受的PsA患者。
  • 患者随机接受IXE 80mg每2周(n=123)、每4周(n=122,起始160mg)或安慰剂(n=118)至第24周。

主要发现

  • 第24周时,无论既往TNFi经验如何,IXE组达到ACR50、HAQ-DI≥0.35改善、MDA、EULAR良好反应和DAPSA≤14的患者比例均显著高于安慰剂组。
  • 对一种TNFi应答不佳者中,IXE组达到ACR50和PASI 100的比例显著高于安慰剂组。
  • 所有疗效指标的改善持续至第52周。
  • 对一种和两种TNFi应答不佳者之间的基线特征无显著差异。

关键数值与推荐

  • ACR50:美国风湿病学会应答标准≥50%改善。
  • PASI 100:银屑病面积和严重程度指数较基线100%改善。
  • HAQ-DI≥0.35改善:健康评估问卷残疾指数改善≥0.35。
  • MDA:最小疾病活动度。
  • EULAR良好反应:DAS28-CRP改善>1.2。

临床怎么用

  • 对于一种或两种TNFi应答不佳的PsA患者,IXE可作为改善疾病活动度和患者报告结局的治疗选择。

局限性

  • 本文为事后分析,原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy of ixekizumab (IXE), a monoclonal antibody selectively targeting interleukin-17A, in patients with inadequate response to one or two TNF inhibitors (TNFi). METHODS: A phase 3 study (SPIRIT-P2; NCT02349295) randomized patients with PsA with inadequate response or intolerance to one or two TNFi to receive 80-mg IXE every 2 weeks (n = 123) or every 4 weeks (n = 122) after a 160-mg starting dose or placebo (PBO; n = 118) through week 24. This post hoc analysis used data from inadequate responders to one or two TNFi, measuring the percentage achieving: ≥50% improvement in ACR response criteria (ACR50) and 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI 100), ACR50, improvement in HAQ-Disability Index (HAQ-DI) ≥0.35, minimal disease activity (MDA), European League Against Rheumatism (EULAR) Good Response Criteria [improvement in Disease Activity Score 28 CRP (DAS28-CRP) >1.2], and Disease Activity in PsA (DAPSA) ≤14. RESULTS: There were no significant differences in baseline characteristics between inadequate responders to one and two TNFi. At week 24, significantly more patients irrespective of previous TNFi experience receiving IXE than PBO achieved ACR50, HAQ-DI ≥0.35 improvement, MDA, EULAR good response, and DAPSA ≤14, and significantly more patients with inadequate response to one TNFi receiving IXE than PBO achieved ACR50 and PASI 100. Improvement persisted in all measures through week 52. CONCLUSION: IXE improved the signs and symptoms of PsA in a population of difficult-to-treat patients with inadequate response to one or two TNFi.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kirkham B, Sesin C, Gellett AM, et al. Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors. Rheumatology (Oxford). 2021. PMID: 33479721. doi:10.1093/rheumatology/keaa824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。